MG-D-1505

MG-D-1505 is an investigational therapeutic candidate developed by Metagone Biotech. It specifically targets phosphorylated Glycogen Synthase Kinase (pGSK), a key enzyme involved in the regulation of glycogen synthesis, protein synthesis, and cell proliferation. The drug is being explored for its potential in treating metabolic and oncological conditions, specifically non-alcoholic steatohepatitis (NASH) and gastric cancer (referred to in some company documents as 'Aspertic Cancer'). By modulating GSK3 signaling, MG-D-1505 aims to address the pathological metabolic pathways in the liver and inhibit tumor growth in gastric malignancies. It is currently in early-stage development, transitioning from preclinical studies to Phase 1 clinical evaluation.